Direct maxacalcitol injection into hyperplastic parathyroids improves skeletal changes in secondary hyperparathyroidism

K. Shiizaki, I. Hatamura, S. Negi, T. Sakaguchi, F. Saji, K. Kunimoto, M. Okamoto, I. Imazeki, Y. Muragaki, T. Akizawa

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Direct maxacalcitol (OCT) injection into a parathyroid gland (PTG) ameliorates several important etiologic factors of resistance to medical treatments for secondary hyperparathyroidism (s-HPT): the upregulations of vitamin D receptor (VDR) and Ca-sensing receptor (CaSR) in PTGs and the regression of PTG hyperplasia by the induction of apoptosis. In this study, we evaluated the bone histomorphology on the basis of maintaining these effects in advanced s-HPT. Five/six nephrectomized Sprague-Dawley rats were fed a high-phosphorus and low-calcium diet for 8 weeks. These rats were divided into four treatment groups: (1) basic uremic (at the baseline), (2) direct OCT single injection into PTGs (DI-OCT) followed by OCT intravenous administration for 4 weeks (IV-OCT), (3) direct vehicle injection and IV-OCT, and (4) no treatment for an additional 4 weeks. The effects of these treatments on serum intact-parathyroid hormone (PTH) level, PTG weight, VDR and CaSR expression levels in PTGs, and bone histomorphometric parameters were investigated. In the DI-OCT+IV-OCT group, the significant decrease in serum intact-PTH level was maintained by the following IV-OCT. A significant decrease in PTG weight and the upregulations of VDR and CaSR expression levels in PTGs were also observed. Bone histomorphometric analysis showed significant improvements in osteitis fibrosa in both cancellous and cortical bones. However, these findings were not observed in the other groups. These results suggest that osteitis fibrosa caused by advanced s-HPT can be successfully reversed by a control of PTH at an appropriate level through the improvement of PTG hyperplasia as induced by DI-OCT+IV-OCT.

Original languageEnglish (US)
Pages (from-to)486-495
Number of pages10
JournalKidney International
Volume70
Issue number3
DOIs
StatePublished - Aug 21 2006

Fingerprint

Secondary Hyperparathyroidism
Parathyroid Glands
Calcium-Sensing Receptors
Calcitriol Receptors
Injections
Parathyroid Hormone
Osteitis
Bone and Bones
Hyperplasia
Up-Regulation
Weights and Measures
R Factors
Therapeutics
Serum
Intravenous Administration
Phosphorus
Sprague Dawley Rats
maxacalcitol
Apoptosis
Diet

Keywords

  • End-stage renal disease
  • Hyperparathyroidism
  • Mineral metabolism
  • Renal osteodystrophy
  • Vitamin D

ASJC Scopus subject areas

  • Nephrology

Cite this

Shiizaki, K., Hatamura, I., Negi, S., Sakaguchi, T., Saji, F., Kunimoto, K., ... Akizawa, T. (2006). Direct maxacalcitol injection into hyperplastic parathyroids improves skeletal changes in secondary hyperparathyroidism. Kidney International, 70(3), 486-495. https://doi.org/10.1038/sj.ki.5001564

Direct maxacalcitol injection into hyperplastic parathyroids improves skeletal changes in secondary hyperparathyroidism. / Shiizaki, K.; Hatamura, I.; Negi, S.; Sakaguchi, T.; Saji, F.; Kunimoto, K.; Okamoto, M.; Imazeki, I.; Muragaki, Y.; Akizawa, T.

In: Kidney International, Vol. 70, No. 3, 21.08.2006, p. 486-495.

Research output: Contribution to journalArticle

Shiizaki, K, Hatamura, I, Negi, S, Sakaguchi, T, Saji, F, Kunimoto, K, Okamoto, M, Imazeki, I, Muragaki, Y & Akizawa, T 2006, 'Direct maxacalcitol injection into hyperplastic parathyroids improves skeletal changes in secondary hyperparathyroidism', Kidney International, vol. 70, no. 3, pp. 486-495. https://doi.org/10.1038/sj.ki.5001564
Shiizaki, K. ; Hatamura, I. ; Negi, S. ; Sakaguchi, T. ; Saji, F. ; Kunimoto, K. ; Okamoto, M. ; Imazeki, I. ; Muragaki, Y. ; Akizawa, T. / Direct maxacalcitol injection into hyperplastic parathyroids improves skeletal changes in secondary hyperparathyroidism. In: Kidney International. 2006 ; Vol. 70, No. 3. pp. 486-495.
@article{a63ae11083fd47f8bd0de180e5457f66,
title = "Direct maxacalcitol injection into hyperplastic parathyroids improves skeletal changes in secondary hyperparathyroidism",
abstract = "Direct maxacalcitol (OCT) injection into a parathyroid gland (PTG) ameliorates several important etiologic factors of resistance to medical treatments for secondary hyperparathyroidism (s-HPT): the upregulations of vitamin D receptor (VDR) and Ca-sensing receptor (CaSR) in PTGs and the regression of PTG hyperplasia by the induction of apoptosis. In this study, we evaluated the bone histomorphology on the basis of maintaining these effects in advanced s-HPT. Five/six nephrectomized Sprague-Dawley rats were fed a high-phosphorus and low-calcium diet for 8 weeks. These rats were divided into four treatment groups: (1) basic uremic (at the baseline), (2) direct OCT single injection into PTGs (DI-OCT) followed by OCT intravenous administration for 4 weeks (IV-OCT), (3) direct vehicle injection and IV-OCT, and (4) no treatment for an additional 4 weeks. The effects of these treatments on serum intact-parathyroid hormone (PTH) level, PTG weight, VDR and CaSR expression levels in PTGs, and bone histomorphometric parameters were investigated. In the DI-OCT+IV-OCT group, the significant decrease in serum intact-PTH level was maintained by the following IV-OCT. A significant decrease in PTG weight and the upregulations of VDR and CaSR expression levels in PTGs were also observed. Bone histomorphometric analysis showed significant improvements in osteitis fibrosa in both cancellous and cortical bones. However, these findings were not observed in the other groups. These results suggest that osteitis fibrosa caused by advanced s-HPT can be successfully reversed by a control of PTH at an appropriate level through the improvement of PTG hyperplasia as induced by DI-OCT+IV-OCT.",
keywords = "End-stage renal disease, Hyperparathyroidism, Mineral metabolism, Renal osteodystrophy, Vitamin D",
author = "K. Shiizaki and I. Hatamura and S. Negi and T. Sakaguchi and F. Saji and K. Kunimoto and M. Okamoto and I. Imazeki and Y. Muragaki and T. Akizawa",
year = "2006",
month = "8",
day = "21",
doi = "10.1038/sj.ki.5001564",
language = "English (US)",
volume = "70",
pages = "486--495",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Direct maxacalcitol injection into hyperplastic parathyroids improves skeletal changes in secondary hyperparathyroidism

AU - Shiizaki, K.

AU - Hatamura, I.

AU - Negi, S.

AU - Sakaguchi, T.

AU - Saji, F.

AU - Kunimoto, K.

AU - Okamoto, M.

AU - Imazeki, I.

AU - Muragaki, Y.

AU - Akizawa, T.

PY - 2006/8/21

Y1 - 2006/8/21

N2 - Direct maxacalcitol (OCT) injection into a parathyroid gland (PTG) ameliorates several important etiologic factors of resistance to medical treatments for secondary hyperparathyroidism (s-HPT): the upregulations of vitamin D receptor (VDR) and Ca-sensing receptor (CaSR) in PTGs and the regression of PTG hyperplasia by the induction of apoptosis. In this study, we evaluated the bone histomorphology on the basis of maintaining these effects in advanced s-HPT. Five/six nephrectomized Sprague-Dawley rats were fed a high-phosphorus and low-calcium diet for 8 weeks. These rats were divided into four treatment groups: (1) basic uremic (at the baseline), (2) direct OCT single injection into PTGs (DI-OCT) followed by OCT intravenous administration for 4 weeks (IV-OCT), (3) direct vehicle injection and IV-OCT, and (4) no treatment for an additional 4 weeks. The effects of these treatments on serum intact-parathyroid hormone (PTH) level, PTG weight, VDR and CaSR expression levels in PTGs, and bone histomorphometric parameters were investigated. In the DI-OCT+IV-OCT group, the significant decrease in serum intact-PTH level was maintained by the following IV-OCT. A significant decrease in PTG weight and the upregulations of VDR and CaSR expression levels in PTGs were also observed. Bone histomorphometric analysis showed significant improvements in osteitis fibrosa in both cancellous and cortical bones. However, these findings were not observed in the other groups. These results suggest that osteitis fibrosa caused by advanced s-HPT can be successfully reversed by a control of PTH at an appropriate level through the improvement of PTG hyperplasia as induced by DI-OCT+IV-OCT.

AB - Direct maxacalcitol (OCT) injection into a parathyroid gland (PTG) ameliorates several important etiologic factors of resistance to medical treatments for secondary hyperparathyroidism (s-HPT): the upregulations of vitamin D receptor (VDR) and Ca-sensing receptor (CaSR) in PTGs and the regression of PTG hyperplasia by the induction of apoptosis. In this study, we evaluated the bone histomorphology on the basis of maintaining these effects in advanced s-HPT. Five/six nephrectomized Sprague-Dawley rats were fed a high-phosphorus and low-calcium diet for 8 weeks. These rats were divided into four treatment groups: (1) basic uremic (at the baseline), (2) direct OCT single injection into PTGs (DI-OCT) followed by OCT intravenous administration for 4 weeks (IV-OCT), (3) direct vehicle injection and IV-OCT, and (4) no treatment for an additional 4 weeks. The effects of these treatments on serum intact-parathyroid hormone (PTH) level, PTG weight, VDR and CaSR expression levels in PTGs, and bone histomorphometric parameters were investigated. In the DI-OCT+IV-OCT group, the significant decrease in serum intact-PTH level was maintained by the following IV-OCT. A significant decrease in PTG weight and the upregulations of VDR and CaSR expression levels in PTGs were also observed. Bone histomorphometric analysis showed significant improvements in osteitis fibrosa in both cancellous and cortical bones. However, these findings were not observed in the other groups. These results suggest that osteitis fibrosa caused by advanced s-HPT can be successfully reversed by a control of PTH at an appropriate level through the improvement of PTG hyperplasia as induced by DI-OCT+IV-OCT.

KW - End-stage renal disease

KW - Hyperparathyroidism

KW - Mineral metabolism

KW - Renal osteodystrophy

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=33746572663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746572663&partnerID=8YFLogxK

U2 - 10.1038/sj.ki.5001564

DO - 10.1038/sj.ki.5001564

M3 - Article

VL - 70

SP - 486

EP - 495

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 3

ER -